BIIB vs. MDT: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BIIB and MDT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BIIB | MDT |
|---|---|---|
| Company Name | Biogen Inc. | Medtronic plc |
| Country | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 20.38 billion USD | 119.44 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | September 17, 1991 | May 2, 1973 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BIIB and MDT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BIIB | MDT |
|---|---|---|
| 5-Day Price Return | 3.00% | 1.35% |
| 13-Week Price Return | 7.38% | 7.19% |
| 26-Week Price Return | 0.39% | 1.11% |
| 52-Week Price Return | -32.55% | 9.90% |
| Month-to-Date Return | 8.59% | 3.30% |
| Year-to-Date Return | -9.11% | 16.70% |
| 10-Day Avg. Volume | 1.42M | 9.16M |
| 3-Month Avg. Volume | 1.49M | 7.63M |
| 3-Month Volatility | 31.01% | 19.48% |
| Beta | 0.09 | 0.79 |
Profitability
Return on Equity (TTM)
BIIB
9.04%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
BIIB’s Return on Equity of 9.04% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
MDT
9.62%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
MDT’s Return on Equity of 9.62% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BIIB
15.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
BIIB’s Net Profit Margin of 15.31% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
MDT
13.90%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
A Net Profit Margin of 13.90% places MDT in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BIIB
20.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 20.80% places BIIB in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
MDT
17.76%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
MDT’s Operating Profit Margin of 17.76% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BIIB | MDT |
|---|---|---|
| Return on Equity (TTM) | 9.04% | 9.62% |
| Return on Assets (TTM) | 5.43% | 5.16% |
| Net Profit Margin (TTM) | 15.31% | 13.90% |
| Operating Profit Margin (TTM) | 20.80% | 17.76% |
| Gross Profit Margin (TTM) | 75.43% | 65.39% |
Financial Strength
Current Ratio (MRQ)
BIIB
2.50
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BIIB’s Current Ratio of 2.50 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
MDT
1.85
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
MDT’s Current Ratio of 1.85 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BIIB
0.36
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BIIB’s Debt-to-Equity Ratio of 0.36 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MDT
0.59
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
MDT’s Debt-to-Equity Ratio of 0.59 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BIIB
4.35
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BIIB’s Interest Coverage Ratio of 4.35 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
MDT
10.20
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
MDT’s Interest Coverage Ratio of 10.20 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BIIB | MDT |
|---|---|---|
| Current Ratio (MRQ) | 2.50 | 1.85 |
| Quick Ratio (MRQ) | 1.79 | 1.42 |
| Debt-to-Equity Ratio (MRQ) | 0.36 | 0.59 |
| Interest Coverage Ratio (TTM) | 4.35 | 10.20 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
MDT
3.01%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.01%, MDT offers a more attractive income stream than most of its peers in the Health Care Equipment & Supplies industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
BIIB
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
MDT
76.98%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
MDT’s Dividend Payout Ratio of 76.98% is in the upper quartile for the Health Care Equipment & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | BIIB | MDT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.01% |
| Dividend Payout Ratio (TTM) | 0.00% | 76.98% |
Valuation
Price-to-Earnings Ratio (TTM)
BIIB
13.27
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BIIB’s P/E Ratio of 13.27 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
MDT
25.55
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
In the lower quartile for the Health Care Equipment & Supplies industry, MDT’s P/E Ratio of 25.55 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BIIB
2.03
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BIIB’s P/S Ratio of 2.03 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
MDT
3.55
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
MDT’s P/S Ratio of 3.55 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BIIB
1.04
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BIIB’s P/B Ratio of 1.04 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
MDT
2.25
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
MDT’s P/B Ratio of 2.25 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | BIIB | MDT |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.27 | 25.55 |
| Price-to-Sales Ratio (TTM) | 2.03 | 3.55 |
| Price-to-Book Ratio (MRQ) | 1.04 | 2.25 |
| Price-to-Free Cash Flow Ratio (TTM) | 11.00 | 22.97 |